Voyager Therapeutics (VYGR) reported new data from its two preclinical programs targeting tau for the treatment of Alzheimer’s disease. Data on ...

Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad ...

Cantor Fitzgerald reaffirmed their overweight rating on shares of Voyager Therapeutics (NASDAQ:VYGR – Free Report) in a research note published on Wednesday morning,Benzinga reports. Cantor Fitzgerald ...

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) have been given an average rating of “Buy” by the nine analysts that are covering the company, Marketbeat.com reports. Eight ...

Voyager Therapeutics announced positive results from the single ascending dose (SAD) trial of its investigational anti-tau antibody, VY7523, which demonstrates safety, tolerability, and dose ...

Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to earnings of $1.25 per share a year ago.

Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing ...

(RTTNews) - Voyager Therapeutics, Inc. (VYGR), Monday, announced the presentation of new preclinical data at the AD/PD 2025 conference, showcasing its tau-targeting gene therapy VY1706 and anti ...

March 31, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported new data from ...

Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical muri ...